MOU strategically important for Invictus Energy


Published 07-MAY-2019 09:32 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Invictus Energy Limited (ASX:IVZ), is pleased to announce that the company and its Cabora Bassa Project partner, One-Gas Resources (Pvt) Ltd (20%), have entered into a non-binding Memorandum of Understanding (MOU) with Sable Chemical Industries Ltd (“Sable”) to progress gas supply from the Cabora Bassa Project subject to a commercial gas discovery being made from SG 4571.

Under the terms of the MOU, Sable would be contracted to take 13 billion cubic feet of gas per year with an option to increase to 26 billion cubic feet.

The supply term of 20 years provides strong revenue visibility in the event that Cabora Bassa is transformed into a source of commercial gas supply.

Not only is this a positive development in terms of Invictus’ prospective earnings profile, but it will be a significant factor in the company being able to satisfactorily negotiate financing terms and/or make the project increasingly attractive for farm-in partners.

Sable is the sole manufacturer of agriculture grade ammonium nitrate fertiliser in Zimbabwe and a potentially large gas consumer.

Under the MOU, Invictus and Sable have agreed to jointly work together and cooperate with regards to investigating the economic and commercial viability of supplying natural gas from the Cabora Bassa Project to the Sable fertilizer plant located in Kwekwe, Zimbabwe.

As indicated below, the Sable plant could be included in the potential SG 4571 pipeline route.

70 million cubic feet per day for 20 years

Invictus managing director Scott Macmillan highlighted the significance of this indicatively sizeable offtake agreement saying, “Signing this MOU with Sable marks a significant milestone in our commercial negotiations as we look to progress the Cabora Bassa Project.

“Sable is the sole producer of nitrogenous fertilizer in Zimbabwe and a well-recognised brand in the country.

“We are proud to work with them to fulfil their ambition of becoming the preferred manufacturer and supplier of fertilizers and other chemical products in Africa.

“The potential gas supply of up to 70 million cubic feet per day for 20 years is a substantial volume which will help underpin the development of any commercial gas discovery we make in the Cabora Bassa Project.”

This MOU demonstrates the huge local gas demand in an energy starved market in Zimbabwe, and Invictus expects to enter into additional gas supply MOUs in the future.

Developments such as these generally provide positive share price momentum, and today’s news along with the prospect of further offtake agreements could be the catalysts for a rerating after the company has flown under the radar during the exploration phase.

Sable Chemicals was established in 1969 and currently operates a fertilizer manufacturing plant which produces ammonium nitrate fertilizers from ammonia gas feedstock which is currently imported from South Africa.

The company has a large plant with the capacity to produce 240,000 tonnes of ammonium nitrate year.

Sable plays an important role in supplying the agricultural sector where demand for competitively priced fertilisers is increasing.

The potential future supply of gas by Invictus is also critical for Sable’s medium-term expansion program aimed at increasing production to 600,000 tonnes of nitrogenous fertilisers.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free